Cargando…

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

The oncogenenic transmembrane tyrosine kinase receptor HER–2/neu is a promising target for treatment of HER–2–overexpressing cancers. The humanized anti‐HER–2/neu antibody Trastuzumab is under clinical evaluation in combination with chemotherapy against breast cancer. The combination of Trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naruse, Ichiro, Fukumoto, Hisao, Saijo, Nagahiro, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2002
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927030/ https://www.ncbi.nlm.nih.gov/pubmed/12036454 http://dx.doi.org/10.1111/j.1349-7006.2002.tb01293.x

Ejemplares similares

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene
por: Kurokawa, Hirokazu, et al.
Publicado: (1997)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines
por: Iwamoto, Yasuo, et al.
Publicado: (1998)

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells
por: Arioka, Hitoshi, et al.
Publicado: (1999)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

CORRECTION
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis
por: Fukuda, Minoru, et al.
Publicado: (1996)

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1997)

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11
por: Ogasawara, Hayato, et al.
Publicado: (1995)

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP
por: Nishio, Kazuto, et al.
Publicado: (1992)

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f
por: Nomoto, Taisuke, et al.
Publicado: (1998)

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)
por: Ohmori, Tohru, et al.
Publicado: (1993)

p16(INK4) Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors
por: Fukuoka, Kazuya, et al.
Publicado: (1997)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations
por: Koay, Debbie C, et al.
Publicado: (2010)

A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents
por: Kuh, Hyo‐Jeong, et al.
Publicado: (2000)

Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines
por: Oshita, Fumihiro, et al.
Publicado: (1994)

Combined time-restricted feeding and cisplatin enhance the anti-tumor effects in cisplatin-resistant and -sensitive lung cancer cells
por: Li, Jianling, et al.
Publicado: (2022)

Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line
por: Ohta, Sei, et al.
Publicado: (1994)

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay
por: Oshita, Fumihiro, et al.
Publicado: (1995)

A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1994)

Present Status and Problems on Molecular Targeted Therapy of Cancer
por: Saijo, Nagahiro
Publicado: (2012)

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
por: Saijo, Nagahiro
Publicado: (2013)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Highlights for ESMO 40: celebration review for lifetime achievement awards
por: Saijo, Nagahiro
Publicado: (2016)

Bromelain Enhances the Anti-tumor Effects of Cisplatin on 4T1 Breast Tumor Model In Vivo
por: Mohamad, Nurul Elyani, et al.
Publicado: (2019)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer
por: Yang, Yu-Xin, et al.
Publicado: (2022)

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
por: Oshita, Fumihiro, et al.
Publicado: (1995)

Combination of (131)I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
por: Vinod, Nagarajan, et al.
Publicado: (2021)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
por: Kurokawa, Y, et al.
Publicado: (2014)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)

Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in hypoxia
por: Chen, Yan, et al.
Publicado: (2021)

Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice
por: Park, Hae-Ran, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c5fve02a2elfo02dc5q0iuhu8m